SUMMARY
During the ENETS Conference, the long-awaited results of the phase 3 COMPETE trial were presented, with the comparison of [177Lu]Lu-edotreotide (Peptide Receptor Radionuclide Therapy = PRRT) vs. everolimus in patients with grade 1–2 gastroenteropancreatic neuroendocrine tumours (GEP NET): PRRT outperformed everolimus in terms of objective response rate and also progression-free survival. Also, an update of the phase 2 OCCLURANDOM trial showed the superiority of PRRT vs. sunitinib in a direct comparison between these two treatment modalities. Alpha-PRRT is advancing in the field of NET as a promising treatment option, with the ACTION-1 trial actively recruiting now in Belgium. NET-IMPRESS, a novel methylation-based assay to diagnose and monitor NET patients using liquid biopsies, was rewarded as the most promising basic research project during the conference and will be tested in broader patient populations. Also, the prominent presence of the patient organisations INCA/VZW NET & MEN at ENETS coincides with the rapidly growing field of treatment options in recent years for our patients with NET.
In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2025;19(4):166–184)
